Premium
The new therapeutic herbal drug HM 0601 and its bioactive compound rutin exert potent antiproliferative activities in mast cells
Author(s) -
Jeong HyunJa,
Yoou MyoungSchook,
Han NaRa,
Hwang Sung Yeoun,
Yoon Kyoung Wan,
Kim HyungMin
Publication year - 2018
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12350
Subject(s) - rutin , thymic stromal lymphopoietin , pharmacology , cytokine , caspase 1 , stimulation , mast cell , medicine , chemistry , traditional medicine , inflammation , immunology , antioxidant , biochemistry , inflammasome
HM 0601 consists of Allium hookeri and Lycium chinense fruit and contains a lot of rutin. Here, we ascertained whether HM 0601 and its major compound rutin reduce proliferation of human mast cell line, HMC ‐1, under thymic stromal lymphopoietin ( TSLP ) stimulation. Therapeutic rutin or HM 0601 treatment considerably reduced proliferation of mast cells without exposing activated HMC ‐1 cells to any cytotoxicity. Reduced levels of mouse double minute 2 and phosphorylated signal transducers and activators of transcription 6 were accompanied by treatment with rutin or HM 0601. In TSLP ‐stimulated cells, rutin or HM 0601 treatment significantly impaired levels of interleukin ( IL )‐13 and Bcl2 expression. Notably, rutin or HM 0601 treatment returned Bax and phosphorylated p53 protein levels and caspase‐3 activities impaired by TSLP . In addition, levels of inflammatory cytokine were considerably reduced by treatment with rutin or HM 0601 on TSLP ‐stimulated cells. In conclusion, these results indicate that HM 0601 can be used as a new therapeutic herbal drug for prevention and therapeutic intervention of allergic inflammatory diseases.